ReP USP - Resultado da busca

Filtros : "Argentina" "FM-MCP" Removidos: "Vitti, Godofredo Cesar" "FCF/FEA/FSP" Limpar

Filtros

Collaboration
Normalized affiliation
Non normalized affiliation
- 3rd division of cardiology, medical university of silesia, katowice, poland (1)
- bayer ag, wuppertal, germany (1)
- dhu fire, université paris-diderot, ap-hp and inserm u-1148, paris, france (1)
- department of cardiology, aarhus university hospital, aarhus, denmark (1)
- department of cardiology, military hospital, budapest, hungary (1)

Countries of institutions of collaboration
- alemanha (1)
- argentina (1)
- bélgica (1)
- canadá (1)
- coréia do sul (1)

Artigo de periodico
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial (2017)
Ohman, E. Magnus; Roe, Matthew T.; Steg, P. Gabriel; James, Stefan K.; Povsic, Thomas J.; White, Jennifer; Rockhold, Frank; Plotnikov, Alexei; Mundl, Hardi; Strony, John; Sun, Xiang; Husted, Steen; Tendera, Michal; Montalescot, Gilles; Bahit, M. Cecilia; Ardissino, Diego; Bueno, Héctor; Claeys, Marc J.; Nicolau, Jose C.; Cornel, Jan H.; Goto, Shinya; Kiss, Róbert Gábor; Güray, Ümit; Park, Duk-Woo; Bode, Christoph; Welsh, Robert C.; Gibson, C. Michael
Source: Lancet. Unidade: FM
Subjects: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, ANTICOAGULANTES, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OHMAN, E. Magnus et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, v. 389, n. 10081, p. 1799-1808, 2017Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(17)30751-1. Acesso em: 06 nov. 2024.
APA
Ohman, E. M., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., White, J., et al. (2017). Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, 389( 10081), 1799-1808. doi:10.1016/S0140-6736(17)30751-1
NLM
Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial [Internet]. Lancet. 2017 ; 389( 10081): 1799-1808.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/S0140-6736(17)30751-1
Vancouver
Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial [Internet]. Lancet. 2017 ; 389( 10081): 1799-1808.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/S0140-6736(17)30751-1

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024